Entity

Time filter

Source Type

Aberdeen, United Kingdom

The University of Aberdeen is a public research university in the city of Aberdeen, Scotland. It is an ancient university founded in 1495 when William Elphinstone, Bishop of Aberdeen, petitioned Pope Alexander VI on behalf of James IV, King of Scots to create King's College. This makes it Scotland's third-oldest university and fifth-oldest in the English-speaking world. The university as it is today was formed in 1860 by a merger between King's College and Marischal College, a second university founded in 1593 in Aberdeen city centre as a Protestant alternative to King's College. Today, the University of Aberdeen is consistently ranked among the top 150 universities in the world and is one of two universities in Aberdeen, the other being The Robert Gordon University.The university's iconic buildings act as symbols of the City of Aberdeen, particularly Marischal College in the city centre and the spire of King's College in Old Aberdeen. There are two campuses; the main King's College campus is at Old Aberdeen approximately two miles north of the city centre, around the original site of King's College, although most campus buildings were constructed in the 20th century during a period of expansion. The university's Foresterhill campus is located next to Aberdeen Royal Infirmary and houses the School of Medicine and Dentistry and School of Medical science.The University has approximately 13,500 students from undergraduate to doctoral level, including many international students. In addition, the university's Centre for Lifelong Learning acts as an extension college, offering higher education courses to the local community even for those without the usual qualifications for admission to degree-level study. A full range of disciplines are offered and in 2012 the university offered over 650 undergraduate degree programmes.Five Nobel Prize winners are associated with the University. Other academics and graduates of the University include many distinguished figures, including: physicist James Clerk Maxwell; Thomas Reid, the founder of the Scottish School of Common Sense and an important figure in the Scottish Enlightenment; philosopher Robert Adamson; educationalist and philosopher Alexander Bain; and theologian William Robinson Clark. Wikipedia.


Brown G.D.,University of Aberdeen
Annual Review of Immunology | Year: 2011

Fungal diseases have emerged as significant causes of morbidity and mortality, particularly in immune-compromised individuals, prompting greater interest in understanding the mechanisms of host resistance to these pathogens. Consequently, the past few decades have seen a tremendous increase in our knowledge of the innate and adaptive components underlying the protective (and nonprotective) mechanisms of antifungal immunity. What has emerged from these studies is that phagocytic cells are essential for protection and that defects in these cells compromise the host's ability to resist fungal infection. This review covers the functions of phagocytes in innate antifungal immunity, along with selected examples of the strategies that are used by fungal pathogens to subvert these defenses. © 2011 by Annual Reviews. All rights reserved. Source


Prosser J.I.,University of Aberdeen
Nature Reviews Microbiology | Year: 2015

Technological advances are enabling the sequencing of environmental DNA and RNA at increasing depth and with decreasing costs. Metagenomic and transcriptomic analysis of soil microbial communities and the assembly of 'population genomes' from soil DNA are therefore now feasible. Although the value of such 'omic' approaches is limited by the associated technical and bioinformatic difficulties, even if these obstacles were eliminated and 'perfect' metagenomes and metatranscriptomes were available, important conceptual challenges remain. This Opinion article considers these conceptual challenges in the context of the current use of omics in soil microbiology, but the main arguments presented are also relevant to the application of omics to marine, freshwater, gut or other environments. © 2015 Macmillan Publishers Limited. All rights reserved. Source


Pennington H.,University of Aberdeen
The Lancet | Year: 2010

Escherichia coli O157 is an uncommon but serious cause of gastroenteritis. This bacterium is noteworthy because a few, but significant, number of infected people develop the haemolytic uraemic syndrome, which is the most frequent cause of acute renal failure in children in the Americas and Europe. Many infections of E coli O157 could be prevented by the more effective application of evidence-based methods, which is especially important because once an infection has been established, no therapeutic interventions are available to lessen the risk of the development of the haemolytic uraemic syndrome. This Review takes into account the evolution and geographical distibution of E coli O157 (and its close pathogenic relatives); the many and varied routes of transmission from its major natural hosts, ruminant farm animals; and other aspects of its epidemiology, its virulence factors, the diagnosis and management of infection and their complications, the repercussions of infection including costs, and prevention. © 2010 Elsevier Ltd. Source


Hub

Patent
University of Aberdeen | Date: 2014-02-13

A hub for transferring power between DC systems. The hub comprises N modules, each for connection to a respective DC system of voltage V


Patent
University of Aberdeen | Date: 2014-11-20

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain fluoro-perhexiline compounds of the following formula (also referred to herein as FPER compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, for example, those which are known to be treated with, or known to be treatable with, perhexiline, including, for example, disorders that are ameliorated by the inhibition of carnitine palmitoyltransferase (CPT); cardiovascular disorders such as: angina pectoris; heart failure (HF); ischaemic heart disease (IHD); cardiomyopathy; cardiac dysrhythmia; stenosis of a heart valve; hypertrophic cardiomyopathy (HCM); coronary heart disease; and other disorders, for example, diabetes and cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

Discover hidden collaborations